Search results for "Ovary"

showing 10 items of 341 documents

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Ta…

2016

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sen…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalEstronemedicine.drug_classBreast NeoplasmsEstrone03 medical and health scienceschemistry.chemical_compoundFollicle-stimulating hormone0302 clinical medicineBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGynecologyTriptorelin PamoateEstradiolbusiness.industryOvaryEstrogensORIGINAL REPORTSLuteinizing Hormonemedicine.diseaseTriptorelinAndrostadienesTamoxifen030104 developmental biologyOncologychemistryChemotherapy AdjuvantEstrogen030220 oncology & carcinogenesisFemaleFollicle Stimulating HormonebusinessTamoxifenmedicine.drugBlood samplingJournal of Clinical Oncology
researchProduct

Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance.

2007

Composizione corporea in relazione alla sindrome dell'ovaio policistico. Increased abdominal fat has been linked to insulin resistance and increased cardiovascular risk. Because many patients with polycystic ovary syndrome (PCOS) present abdominal obesity, it may be the cause of insulin resistance in this disorder.Setting: Fat quantity and distribution were evaluated by dual x-ray absorptiometry at the Departments of Clinical Medicine at the University of Palermo and the University of Naples, Italy.Patients: A total of 110 patients with PCOS and 112 weight-matched controls were studied. Anthropometric data, blood glucose, serum insulin, and testosterone were evaluated. Total, trunk, and cen…

AdultAbdominal fat; Polycystic Ovary Syndrome; Insulin Resistancemedicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryAbdominal FatAdipose tissueBiologyOverweightBiochemistryAbsorptiometry PhotonEndocrinologyInsulin resistanceInternal medicinemedicineHumansInsulinObesityAbdominal obesityInsulinBiochemistry (medical)Sindrome dell'ovaio policisticoOverweightmedicine.diseasePolycystic ovaryObesityEndocrinologymedicine.anatomical_structureAbdomenFemaleInsulin Resistancemedicine.symptomdensità minerale osseainsuino-resistenzaPolycystic Ovary Syndrome
researchProduct

Time-dependent changes in serum 3α-androstanediol glucuronide correlate with hirsutism scores after ovarian suppression

1995

The clinical utility of serum 3 alpha-androstanediol glucuronide level has been controversial. Among the concerns regarding its lack of utility has been the finding that suppression of serum 3 alpha-androstanediol glucuronide does not occur readily with treatment. We hypothesized that because the treatment of hirsutism requires a prolonged duration, a longer observation period is required for changes in serum 3 alpha-androstanediol glucuronide to be measured. Therefore, we studied the clinical and hormonal changes in 11 women treated for hirsutism with a gonadotropin-releasing hormone agonist (GnRH-a) for 1 year. A progressive reduction in Ferriman-Gallwey scores occurred, which was signifi…

AdultAgonistHirsutismmedicine.medical_specialtyAndrosterone glucuronidemedicine.drug_classEndocrinology Diabetes and MetabolismObservation period3-alpha-androstanediol glucuronideAndrosteroneEndocrinologyOvarian suppressionInternal medicinemedicineHumansTestosteronehirsutismTriptorelin Pamoatebusiness.industryObstetrics and Gynecologymedicine.diseaseAndrostane-317-diolEndocrinologyFemaleGlucuronidebusinessPolycystic Ovary SyndromeHormoneGynecological Endocrinology
researchProduct

Does the level of serum antimüllerian hormone predict ovulatory function in women with polycystic ovary syndrome with aging?

2012

Abstract OBJECTIVE: To determine possible prediction of regular menses with aging in anovulatory women with polycystic ovary syndrome (PCOS). DESIGN: Cohort. SETTING: Academic practice. PATIENT(S): A total of 54 anovulatory women with PCOS and 28 age- and weight-matched control subjects. INTERVENTION(S): Blood and ovarian ultrasound at baseline and after 5 years. MAJOR OUTCOME MEASURE(S): Serum antimüllerian hormone (AMH), gonadotropins, androgens, insulin sensitivity, and ovarian ultrasound. RESULT(S): After 5 years, there was a significant decrease in AMH in women with PCOS and control subjects (10 of 54 anovulatory women became ovulatory after 5 years). There was a significant negative c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyAgingSettore MED/09 - Medicina Internaendocrine system diseasesmedia_common.quotation_subjectSettore MED/13 - EndocrinologiaBody Mass IndexCohort StudiesPCOS AMH Fertility Ovarian function Ovulation Aging HyperandrogenismPredictive Value of TestsInternal medicinemedicineHumansProspective StudiesProspective cohort studyOvulationmedia_commonUltrasonographyAntimullerian Hormonebusiness.industryOvaryObstetrics and GynecologyMiddle AgedPolycystic ovarySettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEndocrinologyReproductive MedicinePredictive value of testsCohortAndrogensFemaleInsulin ResistancebusinessBody mass indexBiomarkersGonadotropinsCohort studyAnovulationPolycystic Ovary SyndromeFertility and sterility
researchProduct

Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of th…

2016

Functional hypothalamic amenorrhea is a disorder characterized by cessation of menstrual cycles in the absence of organic disease. In most patients, it occurs in adult life after a stressful event and may be related to a condition of mild chronic energy deprivation. The endocrine pattern is characterized by low estrogen levels with an absent response to a progestogen challenge test and low-normal gonadotropin levels. A few studies have shown that some of these women may have some features of polycystic ovary syndrome; these features include an increased androgen response to gonadotropins, increased anti-Mullerian hormone levels, and altered ovarian morphology or increased ovarian size. Thes…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseases030209 endocrinology & metabolismOvaryOrganic diseaseHypothalamic disease03 medical and health sciencesFollicle-stimulating hormoneYoung Adult0302 clinical medicineInternal medicinemedicineHumansTestosteroneAmenorrheaRetrospective Studies030219 obstetrics & reproductive medicinebiologybusiness.industryOvaryAndrostenedioneObstetrics and GynecologyAnti-Müllerian hormoneDehydroepiandrosteroneOrgan SizeLuteinizing Hormonemedicine.diseasePolycystic ovaryEndocrinologymedicine.anatomical_structureCase-Control Studiesbiology.proteinAmenorrheaFemalemedicine.symptomFollicle Stimulating HormoneLuteinizing hormonebusinessHypothalamic DiseasesPolycystic Ovary SyndromeAmerican journal of obstetrics and gynecology
researchProduct

Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual func…

2017

Since features of polycystic ovary syndrome (PCOS) have been found to be prevalent in women with functional hypothalamic amenorrhea (FHA), we wished to determine what happens to these features after recovery of menstrual function in FHA Design: Prospective cohort study. Twenty-eight women with FHA and 30 age-matched ovulatory controls were studied.Twenty-eight women with FHA and 30 age-matched ovulatory controls were studied. We measured serum estradiol, LH, FSH, testosterone, DHEAS, anti-Mullerian hormone (AMH), body mass index, and ovarian morphology on transvaginal ultrasound.At baseline, 12 of the 28 women (43%) had increased AMH (4.7 ng/mL), and higher testosterone and larger ovaries c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypothalamic amenorrheaYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineHumansTestosteroneProspective StudiesAmenorrheaUltrasonography030219 obstetrics & reproductive medicineEstradiolDehydroepiandrosterone Sulfatebusiness.industryPolycystic ovary syndrome (PCOS)OvaryObstetrics and GynecologyTestosterone (patch)Luteinizing Hormonemedicine.diseasePolycystic ovaryhumanitiesMenstruationEndocrinologyOvarian morphologyFemaleFollicle Stimulating HormonebusinessHypothalamic DiseasesPolycystic Ovary SyndromeGynecological Endocrinology
researchProduct

AMH MEASUREMENT VERSUS OVARIAN ULTRASOUND IN THE DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME IN DIFFERENT PHENOTYPES.

2015

This study was designed to assess the value of serum anti-Müllerian hormone (AMH) in the diagnosis of polycystic ovary syndrome (PCOS) in various phenotypes and to assess ovarian ultrasound parameters.We performed a retrospective matched controlled study of 113 females with various PCOS phenotypes and 47 matched controls. The diagnostic utility of AMH measurement and ovarian ultrasound were compared. Using receiver operating characteristic (ROC) curve analyses, the threshold for AMH (4.7 ng/mL) and ultrasound parameters (follicle number per ovary [FNPO]22 and ovarian volume [OV]8 cc) were established.In the entire cohort, AMH had a low sensitivity of 79%; while FNPO and OV were 93% and 68%,…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismOvaryDiagnostic Techniques Endocrine03 medical and health sciencesFollicleYoung Adult0302 clinical medicineEndocrinologymedicineHumansRetrospective StudiesUltrasonographyGynecology030219 obstetrics & reproductive medicineReceiver operating characteristicbiologybusiness.industryUltrasoundOvaryCase-control studyAnti-Müllerian hormoneRetrospective cohort studyGeneral MedicinePolycystic ovaryfemale genital diseases and pregnancy complicationsmedicine.anatomical_structurePhenotypeROC CurveCase-Control Studiesbiology.proteinFemalebusinessPolycystic Ovary SyndromeEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
researchProduct

Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society

2014

BACKGROUND The diagnosis of polycystic ovary syndrome (PCOS) relies on clinical, biological and morphological criteria. With the advent of ultrasonography, follicle excess has become the main aspect of polycystic ovarian morphology (PCOM). Since 2003, most investigators have used a threshold of 12 follicles (measuring 2-9 mm in diameter) per whole ovary, but that now seems obsolete. An increase in ovarian volume (OV) and/or area may also be considered accurate markers of PCOM, yet their utility compared with follicle excess remains unclear. METHODS Published peer-reviewed medical literature about PCOM was searched using PubMed.gov online facilities and was submitted to critical assessment b…

AdultAnti-Mullerian Hormonemedicine.medical_specialtyAdolescentPopulationOvaryBiologyFollicleYoung AdultOvarian FollicleTerminology as TopicmedicineHumansOvarian follicleeducationGynecologyeducation.field_of_studySurrogate endpointOvaryObstetrics and GynecologyReproducibility of ResultsAnti-Müllerian hormoneAntral folliclePolycystic ovarymedicine.anatomical_structureReproductive Medicinebiology.proteinFemaleBiomarkersPolycystic Ovary Syndrome
researchProduct

Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome

2007

Objective To assess message expression of adiponectin and leptin in visceral and SC fat in women with polycystic ovary syndrome (PCOS) and in control women. Design Prospective clinical trial. Setting Academic medical centers in Mexico City, Mexico and New York, New York. Patient(s) Women with PCOS and control women. Intervention(s) Surgical biopsies of visceral (omental) and subcutaneous (SC) adipose tissue, fasting blood samples, and ultrasound measurements of visceral and SC fat. Main Outcome Measure(s) Messenger RNA assessment of adiponectin and leptin in adipose tissue samples; serum measurements of adiponectin, leptin, glucose, insulin, and hormone levels; measurements of fat quantity …

AdultBlood GlucoseLeptinmedicine.medical_specialtymedicine.medical_treatmentAbdominal FatNew YorkSubcutaneous FatAdipokineAdipose tissueBody Mass IndexSettore MED/13 - EndocrinologiaInsulin resistanceInternal medicineAbdominal fat adiponectin leptin polycystic ovary syndrome insulin resistancemedicineHumansInsulinProspective StudiesRNA MessengerMexicoUltrasonographyAdiponectinbusiness.industryLeptinInsulinnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryEndocrinologyReproductive MedicineCase-Control StudiesFemaleAdiponectinInsulin ResistancebusinessBody mass indexhormones hormone substitutes and hormone antagonistsPolycystic Ovary Syndrome
researchProduct

Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk fa…

2013

Abstract STUDY QUESTION: What alters cardiovascular and metabolic risk factors with aging in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Lipid parameters, mainly low-density lipoprotein (LDL) cholesterol, increase with aging, but not in women who attain ovulatory cycles. WHAT IS KNOWN ALREADY: Cardiovascular and metabolic parameters tend to increase with aging, but this has not been shown in a prospective longitudinal study in women with PCOS. Correlates of these changes have not been identified. STUDY DESIGN: A prospective cohort of 118 hyperandrogenic women with PCOS who were followed from the age of 20-25 years at 5 year intervals for 20 years. PARTICIPANTS/MATERIALS, SE…

AdultBlood GlucoseOvulationmedicine.medical_specialtyWaistSettore MED/09 - Medicina Internamedia_common.quotation_subjectmedicine.medical_treatmentBiologyBody Mass IndexSettore MED/13 - EndocrinologiaRisk FactorsInternal medicineTotal cholesterolPrevalencemedicineHumansInsulinLongitudinal StudiesGonadal Steroid HormonesOvulationmedia_commonMetabolic SyndromeCompeting interestsInsulinPolycystic ovary syndrome (PCOS)RehabilitationMetabolic riskAge Factorsnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseaseLipidsSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologyReproductive MedicineCardiovascular DiseasesPCOS Cardiovascular risk aging hyperandrogenism ovarian function lipid alterationsFemalelipids (amino acids peptides and proteins)Waist CircumferenceMetabolic syndromePolycystic Ovary Syndrome
researchProduct